Clerapliq® protects extracellular matrix proteins to restore the architecture of the ocular matrix in animals. It preserves the natural cellular micro-environment of the wound and the endogenous factors necessary for tissue regeneration.

Each package contains strips of five pipettes with 0.33 mL each, for easy application.
A 10-day supply of an ocular rinse for animals is also included.

Clerapliq, produit vétérinaire

Additional information from Clerapliq®

Clerapliq® is an ophthalmic hygiene product for use in veterinary medicine.

The formulation is based on an RGTA® and dextran in physiological serum aimed at improving corneal lesions in animals.

Place 1 or 2 drops in the affected eye, 2 to 3 times a week.

It is not recommended to use the product on a daily basis. The duration of use can vary from one to several weeks.

Clerapliq® is indicated for use on cats, dogs, sport and race horses, and exotic animals.


Below is a selection of clinical publications on our product.


    Clerapliq -RGTA® or ReGeneraTing Agents mimic heparan sulfate in regenerative medicine: from concept to curing patients Denis Barritault & Marie Gilbert-Sirieix & Kim Lee Rice & Fernando Siñeriz & Dulce Papy-Garcia & Christophe Baudouin & Pascal Desgranges & Gilbert Zakine & Jean-Louis Saffar8 & Johan van Neck Abstract The [...]


    Clerapliq - Jama Ophtalmology clinical trial 2016 Oct 1;134(10):1169-1176. doi: 10.1001/jamaophthalmol.2016.3019. Ahmed M Bata , Katarzyna J Witkowska , Piotr A Wozniak , Klemens Fondi , Gerald Schmidinger , Niklas Pircher , Stephan Szegedi , Valentin Aranha Dos Santos , Anca Pantalon , René M Werkmeister, Gerhard Garhofer , [...]


    Clerapliq - Topical Treatment with a New Matrix Therapy Agent Abdelouahab Aifa, Julie Gueudry, Alexandre Portmann, Agn`es Delcampe, and Marc Muraine PURPOSE. Neurotrophic keratopathy is a degenerative disease of the corneal epithelium resulting from impaired corneal innervation, possibly leading to perforation. We aimed to assess the efficacy and tolerance [...]

Questions about OTR3 ?